Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: (TSXV: $KHRN.V) (CSE: $DIXI_U.C) (OTCQX: $DXBRF) (CSE: $CBDT.C) (TSX: $TGOD.TO)
Delta, Kelowna, BC –August 7, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2019/cannabis-potcasts/08071KHRN-DIXI-DXBRF-CBDT-TGOD.asp
In today’s podcast we look at a few early announcements.
But first, Strainprint™ Technologies Ltd. has launched the next stage of the much-anticipated clinical trial with Israeli based research group Gynica to develop a product formulation to treat endometriosis and its symptoms. This phase will include asking endometriosis sufferers in Canada and Israel to complete an anonymous, comprehensive custom questionnaire about how they use cannabis to treat their symptoms.
Strainprint, the leader in cannabis data and analytics partnered with Israeli researchers at Gynica, a leader in cannabis-based solutions for women's health, in late 2018 to conduct the world's first international clinical study on the use of cannabis to treat endometriosis. The study will leverage Strainprint's database of patient reported outcomes among those who use cannabis to treat endometriosis, which, along with the results of this questionnaire will inform the formulation of a cannabis-based product which will be clinically validated and then available for purchase.
Endometriosis affects approximately 1 in 10 women and it is a condition with limited understanding and treatment options.
“180 million people worldwide experience severe pain daily as a result of tissue similar to the uterine lining migrating to other organs inside the body, causing debilitating pain, infertility, fatigue, gastrointestinal and/or bladder symptoms," says Gynica's Professor Moshe Hod, President of the European Association of Perinatal Medicine and Professor of Obstetrics and Gynecology at Tel Aviv University medical school. "Our objective is to recruit suffering candidates to explore cannabis as a viable therapy in the hopes of developing improved diagnostics and treatments to those who are undertreated by current solutions."
"We believe many women will be eager to take part in this ground-breaking research," says Michelle Arbus, Strainprint's VP of Research. "Our online Strainprint Community already provides a safe space to discuss endometriosis and cannabis treatment with fellow sufferers, and through this questionnaire, participants will have the opportunity to contribute to research and play a more active role in their healthcare with alternative methods not yet explored. Some of these endometriosis sufferers have dealt with excruciating pain for many years and do not tolerate or respond to the current treatment options available. They will now have a chance to be pioneers in a study that could make medical history by helping others not only manage their symptoms, but also greatly improve their quality of life."
Survey participants must be 18 years or older and currently suffer from endometriosis. Once they register to the Strainprint Community, they can request access to an exclusive group, only open to questionnaire participants, giving them access to the questionnaire, forums, specialized endometriosis education materials and more.
Here is how interested candidates can participate:
- Go to https://strainprint.ca/community/groups/endometriosis/
- Click Join the Community or already a member? login here
- You'll be returned to the Endometriosis Group where you'll click request membership.
- Once your group membership has been approved, and you enter the group, click on the survey link.
Once this phase of the study is complete, respondents from both Canada and Israel will be asked if they would like to participate in a clinical trial of a cannabis-based therapy.
Khiron Life Sciences Corp. (TSXV: KHRN)(OTCQB: KHRNF) announced today that it has signed a distribution agreement for its Kuida cosmeceutical brand with Grupo Éxito, Colombia´s market leading retail group and one of the largest retailers in South America.
Grupo Éxito is a Colombian retailer with a successful 110-year presence in the Latin American market and is the only retail company in the region included in the Dow Jones Sustainability index, under the "Emerging Markets" category. Controlled by Casino Guichard-Perrachon and with revenues of U.S.$17 billion in 2018, Grupo Éxito operates 1,533 stores across Colombia, Uruguay, Brazil and Argentina, including 252 Éxito stores and 9 Éxito WOW stores. Under the Company's agreement with Grupo Éxito, Kuida will initially be sold in 5 Éxito WOW stores and 16 traditional format stores.
Introduced by Grupo Éxito in 2018, Éxito WOW represents a new store format aimed at delivering innovative, digitally-integrated customer experiences throughout the Cali, Bogotá, Medellín, and Barranquilla regions of Colombia among others. On introduction to Éxito WOW stores, Kuida will form a cornerstone product line for the retailer's cannabis products category. To support Kuida sales and brand awareness, each Éxito WOW location will host dedicated experience centres, with skin expert consultants on-hand to educate consumers on the brand's proprietary CBDERM technology, as well as its current portfolio of seven skin and personal care products.
Khiron Life Sciences Corp. and Dixie Brands Inc. (CSE: DIXI.U) (OTCQX: DXBRF) also announced that their previously disclosed 50/50 Joint Venture has received conditional approval from the TSX Venture Exchange. With this approval in place, Khiron and Dixie will begin the process of commercialization of the Kuida cosmeceutical product line in the U.S. marketplace, as well as the introduction of Dixie's CBD-infused products into Latin America.
Through the JV, Dixie will be responsible for the distribution of Khiron's portfolio of Kuida cosmeceutical products in the U.S. Kuida products will be broadly distributed through Dixie's established distribution network to U.S. consumers, and are expected to have particular appeal to the growing U.S. Hispanic population, estimated at nearly 60 million.
Further, the conditional TSXV approval allows for the manufacture and commercialization of Dixie's products in Latin America, leveraging Khiron's legislative, sales and marketing abilities and Dixie's extensive and market-proven product line. It is anticipated that Dixie CBD-based products will be commercialized in Latin America beginning in 2020. The JV also creates a framework for the development of new products and brands tailored to Latin America, allowing Dixie and Khiron to take full advantage of opportunities resulting from advancements in cannabis legalization in the region. The conditional TSXV approval covers operations in Colombia, Chile and Uruguay; additional applications will be made to the TSXV as more Latin American countries legalize the use of cannabis.
Alvaro Torres, Khiron CEO and Director, comments: "With a strong JV leadership, sales and marketing team in place, this regulatory approval positions us to accelerate activities in both our core Latin American markets and in the U.S. Bringing the full Kuida product line to U.S. consumers is an important development as we build capacity and market access to expand Kuida brand distribution into new jurisdictions globally."
Dixie Brands Inc. and AriZona, maker of the #1 selling iced tea in America, also announced signing a binding letter of intent on Friday, August 2nd, 2019, to partner for the production, distribution and sale of cannabis-infused products containing THC.
Under the terms of this deal between Dixie Brands Inc., and the AriZona™ brand, through its affiliated entity, Herbal Enterprises, LLC, will direct brand and product conceptual design; while Dixie Brands will develop, formulate, manufacture and distribute the new portfolio of AriZona branded THC infused consumer packaged goods.
"AriZona has always led the way in product innovation," said Don Vultaggio, Chairman, AriZona Beverages. "The cannabis market is an important emerging category, and we've maintained our independence as a private business to be positioned to lead and seize generation-defining opportunities exactly like this one. The Cannabis category is an ideal space to bring the flavor and fun of AriZona into new and exciting products, and we selected Dixie Brands as our partner to bring these products to market after touring their best in class manufacturing facilities, and spending considerable time building a strong relationship with their management. Both companies share a heritage of quality, excellence in manufacturing, and doing things the right way, and we look forward to all this partnership has in store."
"AriZona is a power brand," said Chuck Smith, CEO Dixie Brands, "and the most iconic and recognized CPG brand to extend into the cannabis market, providing the evolving cannabis consumer with a fun and flavorful experience alongside an iconic brand they know and love. For nearly a decade Dixie Brands has crafted award-winning cannabis-infused products creating some of the most recognized and trusted brands in the industry, and we are thrilled to have found a partner that shares our values. This partnership marks a watershed moment for the popularization and expansion of the cannabis sector overall, and is another large step forward for Dixie Brands' strategy to build a house of famous cannabis CPG brands."
EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) announced that it has entered into a strategic partnership with Endocanna Health Inc., a research and development biotechnology company specializing in endocannabinioid DNA testing, and a partly owned subsidiary of Heritage Cannabis (CSE: CANN).
Endocanna will manufacture its patent-pending Endocannabinoid DNA Test Kits for and license its proprietary DNA technology to Empower. Empower will immediately make the Endocanna kits available to its corporate owned medical clinics that include 165,000 patients in Oregon, Arizona, Washington State and Nevada. The Company plans to include the DNA Test Kits as a standard offering in the Sun Valley Health franchise program, and has commenced it's roll-out in the United States.
"We continue to focus our initiatives on patient care and wellbeing, ensuring we have the ability to provide best-in-class care and advice using the most advanced technology available." said Steven McAuley, Empowers Chairman & CEO. "The Endocanna DNA Test Kit can give our physicians the potential to have even greater insight into each individual patient's propensity for success, on how CBD based therapies may interact with their individual regulatory system."
The Kits are designed to provide consumers with personalized data about how cannabidiol (CBD) and other cannabinoids may interact with their body, plus the technology may allow the company to provide patients with science-backed cannabis product suggestions based on their specific DNA.
"Using Endocanna Health's proprietary DNA report, we can personalize and provide a cannabinoid wellness protocol tailored to an individual's needs." said Len May, CEO & Co-Founder of Endocanna Health. "Empower and their Sun Valley Health clinic network, provides an immediate opportunity for us to work with physicians and patients to develop advanced science surrounding the endocannabinioid system and CBD based therapies."
The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (OTC:TGODF) announced that it has submitted an application to list its common shares on the NASDAQ.
The listing of TGOD's shares on the NASDAQ will be subject to a number of regulatory requirements, including registration of the common shares under the U.S. Securities Exchange Act of 1934 and a determination by the NASDAQ that TGOD has satisfied all applicable listing requirements. Subject to approval for listing, the common shares will continue to trade on the TSX Exchange (TSX) under 'TGOD', which is also the reserved symbol for the NASDAQ application.
"This is an important step in the growth of TGOD, one that will broaden our investor base and increase access for international investors as we build the leading global organic cannabis brand,'' commented Brian Athaide, CEO of TGOD. "Our team remains focused on executing our business plan and creating value for our shareholders."
Alimentation Couche-Tard Inc. (TSX: ATD.A) (TSX: ATD.B) and Fire & Flower Holdings Corp. (TSX: FAF) today confirmed the closing of their transaction previously announced on July 24, 2019. In addition, the common shares in the capital of Fire & Flower commenced trading on the Toronto Stock Exchange as of August 7, 2019.
The Transaction includes the issuance today by Fire & Flower of an 8.0% unsecured convertible debenture to an indirect wholly-owned subsidiary of Couche-Tard in the aggregate principal amount of approximately $26.0M, which principal amount of debenture is convertible by the Investor into 24,289,706 Common Shares at a price of $1.07 per Common Share, representing a 9.9% ownership interest in Fire & Flower on a pro forma fully-diluted basis. The Investor has also been issued Common Share purchase warrants that, if exercised in full in accordance with the terms thereof, will subsequently increase the Investor's ownership interest to 50.1% of Fire & Flower on a pro forma fully-diluted basis.
In connection with the closing of the Transaction, Fire & Flower announced the appointment of Jeremy Bergeron as Couche-Tard's initial nominee to Fire & Flower's board of directors.
"Through this strategic investment, we reinforce our intention to become a key player in North America's cannabis industry," said Brian Hannasch, President and CEO of Couche-Tard. "We are excited to see what we can achieve together with Fire & Flower, as we further expand in Canada and look to leverage our presence in the United States and beyond."
"Combining Couche-Tard's expertise in scaling retail stores with Fire & Flower's retail experience and proprietary HifyreTM digital platform positions our company extremely well to capitalize on new cannabis markets as they emerge," added Trevor Fencott, Fire & Flower's Chief Executive Officer.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
